Elevated expression of CUEDC2 protein confers endocrine resistance in breast cancer

Nature Medicine

Volumn 17, Issue 6, 2011, Pages 708-714

  Pan, Xin ^a   Zhou, Tao ^a   Tai, Yan Hong ^b,c   Wang, Chenguang ^d   Zhao, Jie ^a   Cao, Yuan ^c   Chen, Yuan ^a   Zhang, Pei Jing ^a   Yu, Ming ^a   Zhen, Cheng ^a   Mu, Rui ^a   Bai, Zhao Fang ^a   Li, Hui Yan ^a   Li, Ai Ling ^a   Liang, Bing ^a   Jian, Zhao ^a   Zhang, Wei Na ^a   Man, Jiang Hong ^a   Gao, Yan Fei ^a   Gong, Wei Li ^a   Wei, Li Xin ^b   Zhang, Xue Min ^a   more..

^a NATIONAL CENTER OF BIOMEDICAL ANALYSIS   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c 90th Hospital of Jinan   (China)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CUE DOMAIN CONTAINING PROTEIN 2; PROTEASOME; TAMOXIFEN; UBIQUITINATED PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESISTANCE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARRIER PROTEINS; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; I-KAPPA B KINASE; MEMBRANE PROTEINS; PHOSPHORYLATION; RECEPTORS, PROGESTERONE; TAMOXIFEN; UBIQUITINATION;

EID: 79958176952     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2369     Document Type: Article

References (44)

1. Donaldson, K.M., Yin, H., Gekakis, N., Supek, F. & Joazeiro, C.A. Ubiquitin signals protein trafficking via interaction with a novel ubiquitin binding domain in the membrane fusion regulator, Vps9p. Curr. Biol. 13, 258-262 (2003). (Pubitemid 36178306)
2. Ponting, C.P. Proteins of the endoplasmic-reticulum-associated degradation pathway: domain detection and function prediction. Biochem. J. 351, 527-535 (2000).
3. Shih, S.C. et al. A ubiquitin-binding motif required for intramolecular monoubiquitylation, the CUE domain. EMBO J. 22, 1273-1281 (2003). (Pubitemid 36362691)
4. Zhang, P.J. et al. CUE domain containing 2 regulates degradation of progesterone receptor by ubiquitin-proteasome. EMBO J. 26, 1831-1842 (2007).
5. Li, H.Y. et al. Deactivation of the kinase IKK by CUEDC2 through recruitment of the phosphatase PP1. Nat. Immunol. 9, 533-541 (2008).
6. Harvey, J.M., Clark, G.M., Osborne, C.K. & Allred, D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 17, 1474-1481 (1999). (Pubitemid 29220854)
7. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351, 1451-1467 (1998).
8. Nadji, M., Gomez-Fernandez, C., Ganjei-Azar, P. & Morales, A.R. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am. J. Clin. Pathol. 123, 21-27 (2005). (Pubitemid 40066168)
9. Osborne, C.K., Schiff, R., Fuqua, S.A. & Shou, J. Estrogen receptor: current understanding of its activation and modulation. Clin. Cancer Res. 7, 4338s-4342s (2001). (Pubitemid 34031577)
10. Klinge, C.M. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res. 29, 2905-2919 (2001). (Pubitemid 32685217)
11. Schiff, R., Massarweh, S., Shou, J. & Osborne, C.K. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin. Cancer Res. 9, 447S-454S (2003). (Pubitemid 36105786)
12. Ma, C.X. et al. Human aromatase: gene resequencing and functional genomics. Cancer Res. 65, 11071-11082 (2005). (Pubitemid 41713378)
13. Ingle, J.N. Pharmacogenomics of tamoxifen and aromatase inhibitors. Cancer 112, 695-699 (2008). (Pubitemid 351186391)
14. Johnston, S.R. & Dowsett, M. Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat. Rev. Cancer 3, 821-831 (2003). (Pubitemid 37376980)
15. Baum, M. et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359, 2131-2139 (2002). (Pubitemid 34694019)
16. Jensen, E.V. & Jordan, V.C. The estrogen receptor: a model for molecular medicine. Clin. Cancer Res. 9, 1980-1989 (2003). (Pubitemid 36687616)
17. MacGregor, J.I. & Jordan, V.C. Basic guide to the mechanisms of antiestrogen action. Pharmacol. Rev. 50, 151-196 (1998). (Pubitemid 28305723)
18. Jordan, V.C. & O'Malley, B.W. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J. Clin. Oncol. 25, 5815-5824 (2007).
19. Clarke, R. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22, 7316-7339 (2003). (Pubitemid 37492898)
20. Musgrove, E.A. & Sutherland, R.L. Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 9, 631-643 (2009).
21. Riggins, R.B., Bouton, A.H., Liu, M.C. & Clarke, R. Antiestrogens, aromatase inhibitors and apoptosis in breast cancer. Vitam. Horm. 71, 201-237 (2005). (Pubitemid 43631307)
22. Ring, A. & Dowsett, M. Mechanisms of tamoxifen resistance. Endocr. Relat. Cancer 11, 643-658 (2004). (Pubitemid 40065543)
23. Johnston, S.R. et al. Changes in estrogen receptor, progesterone receptor and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res. 55, 3331-3338 (1995).
24. Chu, I. et al. Src promotes estrogen-dependent estrogen receptor α proteolysis in human breast cancer. J. Clin. Invest. 117, 2205-2215 (2007). (Pubitemid 47219565)
25. Shao, W., Keeton, E.K., McDonnell, D.P. & Brown, M. Coactivator AIB1 links estrogen receptor transcriptional activity and stability. Proc. Natl. Acad. Sci. USA 101, 11599-11604 (2004). (Pubitemid 39095342)
26. Fan, M., Nakshatri, H. & Nephew, K.P. Inhibiting proteasomal proteolysis sustains estrogen receptor-α activation. Mol. Endocrinol. 18, 2603-2615 (2004). (Pubitemid 39482052)
27. Sutherland, R.L. & Musgrove, E.A. Cyclins and breast cancer. J. Mammary Gland Biol. Neoplasia 9, 95-104 (2004). (Pubitemid 39137499)
28. Kenny, F.S. et al. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin. Cancer Res. 5, 2069-2076 (1999). (Pubitemid 29399260)
29. Olopade, O.I. et al. Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J. Sci. Am. 3, 230-237 (1997).
30. Bernoux, A. et al. Estrogen receptor negative and progesterone receptor positive primary breast cancer: pathological characteristics and clinical outcome. Institut Curie Breast Cancer Study Group. Breast Cancer Res. Treat. 49, 219-225 (1998). (Pubitemid 28416787)
31. Yamashita, H. Current research topics in endocrine therapy for breast cancer. Int. J. Clin. Oncol. 13, 380-383 (2008).
32. Gown, A.M. Current issues in ER and HER2 testing by IHC in breast cancer. Mod. Pathol. 21 Suppl 2, S8-S15 (2008). (Pubitemid 351592775)
33. Lippman, M.E. & Allegra, J.C. Quantitative estrogen receptor analyses: the response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free interval. Cancer 46, 2829-2834 (1980). (Pubitemid 11205642)
34. Jaiyesimi, I.A., Buzdar, A.U., Decker, D.A. & Hortobagyi, G.N. Use of tamoxifen for breast cancer: twenty-eight years later. J. Clin. Oncol. 13, 513-529 (1995).
35. Normanno, N. et al. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr. Relat. Cancer 12, 721-747 (2005). (Pubitemid 41815773)
36. Baselga, J. & Norton, L. Focus on breast cancer. Cancer Cell 1, 319-322 (2002). (Pubitemid 41039134)
37. Arpino, G., Wiechmann, L., Osborne, C.K. & Schiff, R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr. Rev. 29, 217-233 (2008). (Pubitemid 351519691)
38. Baldwin, A.S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J. Clin. Invest. 107, 241-246 (2001). (Pubitemid 32157954)
39. Kim, D.W. et al. Activation of NF-κB/Rel occurs early during neoplastic transformation of mammary cells. Carcinogenesis 21, 871-879 (2000). (Pubitemid 30265128)
40. Gutierrez, M.C. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2 and p38 mitogen-activated protein kinase. J. Clin. Oncol. 23, 2469-2476 (2005). (Pubitemid 47050837)
41. Rochefort, H., Glondu, M., Sahla, M.E., Platet, N. & Garcia, M. How to target estrogen receptor-negative breast cancer? Endocr. Relat. Cancer 10, 261-266 (2003). (Pubitemid 36758652)
42. Sharma, D., Saxena, N.K., Davidson, N.E. & Vertino, P.M. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res. 66, 6370-6378 (2006).
43. Giacinti, L., Claudio, P.P., Lopez, M. & Giordano, A. Epigenetic information and estrogen receptor α expression in breast cancer. Oncologist 11, 1-8 (2006). (Pubitemid 43152681)
44. Pan, X. et al. Induction of SOX4 by DNA damage is critical for p53 stabilization and function. Proc. Natl. Acad. Sci. USA 106, 3788-3793 (2009).